Exclusive Online Content
New Clinical Trial Data Demonstrates BD Libertas Wearable Injector as a Drug Delivery System
BD (Becton, Dickinson and Company) recently announced publication of the results from a 52-subject human clinical trial with the BD Libertas Wearable Injector…..
Passage Bio Teams With Catalent to Start cGMP Manufacturing for Lead Gene Therapy Products
Passage Bio, Inc. and Catalent recently announced that manufacturing operations have commenced to support adeno-associated virus (AAV) production for Passage Bio’s lead….
Syneos Health & ConcertAI Announce Strategic Collaboration to Accelerate the Use of Real World Evidence & AI to Advance Oncology Research
Syneos Health and ConcertAI recently announced a strategic collaboration to accelerate and streamline the implementation of novel oncology clinical trial research and study designs…..
Theratechnologies Announces New Findings for its Lead Investigational Compound for the Treatment of Several Additional Cancers
Theratechnologies Inc. recently announced new preclinical in vivo findings regarding the efficacy and tolerability of its novel investigational proprietary peptide-drug conjugate (PDC), TH1902, for the….
Excellence in Production: A Critical Contribution to the Pharmaceutical Industry
When it comes to the production of high-quality pharmaceuticals, excellence is the name of the game – in all production areas. It is the overarching goal of a well-defined course of action for….
WEBINAR ALERT! – Beyond Elemental Impurities: New Applications of ICP-MS
During this educational event, scientific experts will discuss several newer applications of ICP-MS in the pharmaceutical industry that capitalize on the technique’s versatility beyond the scope of elemental impurities.
Vectura Signs Development Agreement With Kinaset Therapeutics
Vectura Group plc recently announced it has signed a global outlicense and development agreement with Kinaset Therapeutics Inc. for the development and commercialization of….
BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity
BD (Becton, Dickinson and Company), a leading global medical technology company, recently announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity….
Lonza Expands Development & Manufacturing Capabilities
Lonza recently announced a significant investment to expand its particle engineering and drug product capabilities to meet increased market demand at its Bend, OR, site…..
Kindeva & BOL Pharma Sign Agreement for Development of Inhaled Cannabinoid Products
Kindeva Drug Delivery and Breath of Life International recently signed an agreement to study the feasibility of multiple inhaled cannabinoid products…..
EXCLUSIVE ONLINE CONTENT
Credence MedSystems Receives Strategic Investment From Novartis
Credence MedSystems recently announced that Novartis has made a strategic investment in the company. The investment will advance ongoing development and scaling of Credence’s innovative drug delivery systems….
Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory
Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to….
ViGeneron Announces Research Collaboration With Daiichi Sankyo to Evaluate Novel Ophthalmic Gene Therapy
ViGeneron GmbH recently announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited for delivering….
Molecular Templates Announces FDA Acceptance of IND Application for a PD-L1-Targeted Engineered Toxin Body Enabled With Proprietary Antigen Seeding Technology
Molecular Templates, Inc. recently announced the US FDA has accepted its Investigational New Drug (IND) application for MT-6402, a next-generation ETB targeting PD-L1 that is enabled with….
Clene Nanomedicine Receives Patent Notice of Allowance for using Gold Nanocrystals for Treating MS
Clene Inc. recently announced its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, was issued a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its invention for….